ECSP088335A - Compuestos de pirimidina amida como inhibidores de pgds - Google Patents

Compuestos de pirimidina amida como inhibidores de pgds

Info

Publication number
ECSP088335A
ECSP088335A EC2008008335A ECSP088335A ECSP088335A EC SP088335 A ECSP088335 A EC SP088335A EC 2008008335 A EC2008008335 A EC 2008008335A EC SP088335 A ECSP088335 A EC SP088335A EC SP088335 A ECSP088335 A EC SP088335A
Authority
EC
Ecuador
Prior art keywords
amida
pyrimidine compounds
compound
pgds inhibitors
pgds
Prior art date
Application number
EC2008008335A
Other languages
English (en)
Inventor
Suzanne C Aldous
John Ziqi Jiang
Jinqi Lu
Liang Ma
Lan Mu
Harry Randall Munson
Jeffrey Stephen Sabol
Sukanthini Thurairatnam
Christopher Loren Vandeusen
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ECSP088335A publication Critical patent/ECSP088335A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a un compuesto de fórmula (I):en la que R1, R2, R3 y L1 son como se han definido anteriormente, una composición farmacéutica que comprende el compuesto, y el uso del compuesto para tratar trastornos alérgicos y/o inflamatorios, particularmente trastornos tales como rinitis alérgica, asma y/o enfermedad pulmonar obstructiva crónica (COPD).
EC2008008335A 2005-10-04 2008-04-02 Compuestos de pirimidina amida como inhibidores de pgds ECSP088335A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04

Publications (1)

Publication Number Publication Date
ECSP088335A true ECSP088335A (es) 2008-05-30

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008335A ECSP088335A (es) 2005-10-04 2008-04-02 Compuestos de pirimidina amida como inhibidores de pgds

Country Status (27)

Country Link
US (1) US8202863B2 (es)
EP (1) EP1937652B1 (es)
JP (1) JP5452925B2 (es)
KR (1) KR101457966B1 (es)
CN (2) CN101282943A (es)
AR (1) AR056871A1 (es)
AU (1) AU2006299428B2 (es)
BR (1) BRPI0616815A2 (es)
CA (1) CA2624749C (es)
CR (1) CR9832A (es)
DO (1) DOP2006000210A (es)
EC (1) ECSP088335A (es)
ES (1) ES2514471T3 (es)
IL (1) IL190411A (es)
MA (1) MA29925B1 (es)
MY (1) MY151172A (es)
NO (1) NO20082000L (es)
NZ (1) NZ567208A (es)
PE (2) PE20110118A1 (es)
RU (1) RU2420519C2 (es)
SG (1) SG166121A1 (es)
TN (1) TNSN08104A1 (es)
TW (1) TWI415839B (es)
UA (1) UA93213C2 (es)
UY (1) UY29840A1 (es)
WO (1) WO2007041634A1 (es)
ZA (1) ZA200802222B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ566722A (en) * 2005-09-15 2010-11-26 Orchid Res Lab Ltd Novel pyrimidine carboxamides
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
MX2008013194A (es) 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
CA2679198C (en) * 2007-02-26 2011-07-12 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
ES2663517T3 (es) * 2007-08-27 2018-04-13 Dart Neuroscience (Cayman) Ltd Compuestos terapéuticos de isoxazol
MX2010003864A (es) 2007-10-11 2010-06-01 Vertex Pharma Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
JP5555169B2 (ja) * 2007-10-11 2014-07-23 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
AU2008310663A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
EP2215054B8 (en) * 2007-11-13 2012-02-08 Evotec AG Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
US8188280B2 (en) * 2008-02-06 2012-05-29 Msd K.K. 3-substituted sulfonyl piperidine derivative
EP2286221A4 (en) * 2008-05-13 2011-07-06 Cayman Chem Co METHOD FOR TESTING COMPOUNDS OR MEANS FOR THEIR POSSIBILITY TO DISPLACE STRONG LIGANDS OF THE HEMATOPOIETIC PROSTAGLANDIN D-SYNTHASE
US20110306597A1 (en) 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
WO2009153720A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
BRPI0919004A2 (pt) 2008-09-22 2019-09-24 Cayman Chem Co composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
WO2010056044A2 (ko) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
AU2010222122B2 (en) 2009-03-09 2013-06-27 Taiho Pharmaceutical Co., Ltd. Piperazine compound capable of inhibiting prostaglandin D synthase
BR112012007635B1 (pt) * 2009-10-08 2019-07-09 Sanofi Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação
EP2527340B1 (en) * 2010-01-22 2016-08-17 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a pgds inhibitory effect
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
US9199976B2 (en) 2010-06-01 2015-12-01 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
WO2012033069A1 (ja) 2010-09-07 2012-03-15 大鵬薬品工業株式会社 プロスタグランジンd合成酵素を阻害するピペリジン化合物
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
CN104159587A (zh) 2012-01-06 2014-11-19 南佛罗里达大学 组合物、使用方法、以及治疗方法
WO2014029193A1 (en) * 2012-08-24 2014-02-27 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
CN108430992A (zh) 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
WO2017160832A1 (en) * 2016-03-14 2017-09-21 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
EP3638672A1 (en) 2017-06-13 2020-04-22 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
US11357759B2 (en) 2017-10-29 2022-06-14 China Medical University Composition including ADAM9 inhibitor and the use thereof
EP3724197A1 (en) 2017-12-13 2020-10-21 GlaxoSmithKline Intellectual Property Development Ltd Fused pyridines which act as inhibitors of h-pgds
JP7428692B2 (ja) * 2018-03-23 2024-02-06 ステップ ファーマ エス．エー．エス Ｃｔｐｓ１阻害剤としてのアミノピリミジン誘導体
JP2022506850A (ja) 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 化学化合物
CA3182912A1 (en) * 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
US20230339937A1 (en) 2020-06-19 2023-10-26 Sato Pharmaceutical Co., Ltd. Condensed ring compounds that inhibit h-pgds
JP2023546996A (ja) * 2020-10-23 2023-11-08 ニンバス クロソー， インコーポレイテッド Ｃｔｐｓ１阻害剤およびその使用
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
WO2023091456A1 (en) * 2021-11-17 2023-05-25 Chdi Foundation, Inc. N-(2h-indazol-5-yl)pyrazine-2-carboxamide derivatives and similar compounds as htt modulators for the treatment of huntington's disease
EP4450502A4 (en) * 2021-12-17 2025-06-11 Sato Pharmaceutical Co., Ltd. AZAINDOLE DERIVATIVE INHIBITING H-PGDS
JPWO2023163140A1 (es) * 2022-02-28 2023-08-31

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2934543A1 (de) * 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
US7115750B1 (en) * 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
JPWO2004011430A1 (ja) * 2002-07-25 2005-11-24 アステラス製薬株式会社 ナトリウムチャネル阻害剤
WO2004011440A1 (ja) * 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
ATE450533T1 (de) 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
ES2257616T3 (es) * 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
WO2005032493A2 (en) 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
WO2005072681A2 (en) * 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain.
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Also Published As

Publication number Publication date
AU2006299428B2 (en) 2012-04-26
MY151172A (en) 2014-04-30
UY29840A1 (es) 2007-05-31
JP2009510170A (ja) 2009-03-12
CR9832A (es) 2008-06-18
DOP2006000210A (es) 2007-06-15
KR20080050611A (ko) 2008-06-09
RU2008117170A (ru) 2009-11-10
IL190411A0 (en) 2008-11-03
EP1937652A1 (en) 2008-07-02
MA29925B1 (fr) 2008-11-03
WO2007041634A1 (en) 2007-04-12
CN101538246A (zh) 2009-09-23
AR056871A1 (es) 2007-10-31
ZA200802222B (en) 2009-09-30
TW200812977A (en) 2008-03-16
US20080227782A1 (en) 2008-09-18
NZ567208A (en) 2011-03-31
PE20070589A1 (es) 2007-06-22
EP1937652B1 (en) 2014-07-30
CN101538246B (zh) 2014-07-16
UA93213C2 (en) 2011-01-25
CN101282943A (zh) 2008-10-08
KR101457966B1 (ko) 2014-11-04
AU2006299428A1 (en) 2007-04-12
TWI415839B (zh) 2013-11-21
PE20110118A1 (es) 2011-03-08
JP5452925B2 (ja) 2014-03-26
IL190411A (en) 2013-09-30
US8202863B2 (en) 2012-06-19
SG166121A1 (en) 2010-11-29
TNSN08104A1 (en) 2009-07-14
NO20082000L (no) 2008-06-09
RU2420519C2 (ru) 2011-06-10
BRPI0616815A2 (pt) 2011-07-05
ES2514471T3 (es) 2014-10-28
CA2624749C (en) 2011-08-16
CA2624749A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
UY29840A1 (es) Compuestos de pirimidina amida como inhibidores de pgds
SV2009002861A (es) Compuestos de pirimidina amida como inhibidores de pgds
MX2009009443A (es) Compuestos de pirimidina hidrazida como inhibidores de pgds.
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
HN2011000874A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
BR0107934A (pt) Carboxamidas de pirimidina úteis como inibidores de isozimas pde4
GT200600193A (es) Imidazoquinolines como inhibidores de lipidos kinase
CO6382129A2 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o provencion de diabetes
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
UY32938A (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
UY31687A1 (es) Nueva dosificacion y formulacion
NO20075113L (no) Proteinkinaseinhibitorer
UY29506A1 (es) Nuevas formas cristalinas de bromuro de tiotropio
CL2011002463A1 (es) Compuestos heterociclicos, agonistas del receptor de glucocorticoide; composicion farmaceutica que comprende a dicho compuesto; composicion farmaceutica; kit farmaceutico; uso del compuesto para tratar el asma, enfermedad pulmonar obstructiva cronica o rinitis alergica.
CL2011002461A1 (es) Compuestos derivados de tipo amida de compuestos [3,2-c] pirazol con actividad glucocorticoide utiles en condiciones inflamatorias y alergicas como asma, epoc o rinitis alergica.
UY28720A1 (es) Uso de pteridinas sustituidas para el tratamiento de enfermedades de la vías respiratorias
CL2008003495A1 (es) Compuestos derivados de pirazol; composicion farmaceutica, metodo de preparacion y; su uso para tratar una enfermedad mediada por 5-lo tal como asma, broncocontriccion, enfisema, enfermedades obstructivas o inflamatorias de las vias respiratorias, bronquitis, lesion pulmonar aguda, bronquiectasia, rinitis alergica, entre otras.
EA201070927A1 (ru) Двойные фармакофоры-pde4-мускариновые антагонисты
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
DOP2010000239A (es) Farmacoforos duales-antagonistas muscarinicos de pde4
UY30934A1 (es) Producto farmacéutico combinacion de un antagonista del receptor de quimioquina 1 (ccr1) y un antagonista muscarinico, composiciones farmacéuticas y aplicaciones.
UY30988A1 (es) Compuestos de pirimidina hidrazida como inhibidores de pgds
CL2012000885A1 (es) Compuestos derivados de feniloxadiazol, inhibidores de las prostaglandinas sintasa (pgds); procedimiento de preparacion de dichos compuestos; compuestos intermediarios; composicion farmaceutica que comprende dichos compuestos, util para tratar un trastorno inflamatorio o alergico.